8-K: Procept Biorobotics Q1 2026 Earnings Report

Procept Biorobotics reported a 20% increase in first-quarter revenue to $83.1 million, driven by strong U.S. system sales and improved pricing, alongside a 30% rise in U.S. procedures.

Summary

• Procept Biorobotics announced first-quarter 2026 revenue of $83.1 million, a 20% increase year-over-year.
• U.S. procedures reached approximately 12,200, up 30% from the prior year.
• U.S. system revenue grew 25% to $23.4 million, and handpiece/consumable revenue increased 13% to $43.0 million.
• International revenue rose 25% to $11.1 million.
• Gross margin improved to 65% from 64% in the prior year period.
• Operating expenses increased to $86.6 million from $71.6 million, due to investments in commercial expansion, innovation, and a prostate cancer trial.
• Net loss widened to $31.6 million from $24.7 million in the prior year.
• Adjusted EBITDA loss was $18.1 million, compared to a loss of $15.8 million in the prior year.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive report, with strong revenue and procedure growth, but offset by an increasing net loss and wider Adjusted EBITDA loss, reflecting ongoing investment.

Positives

• Total revenue increased by 20% to $83.1 million in Q1 2026 compared to Q1 2025.
• U.S. procedures saw a significant increase of approximately 30% to 12,200 in Q1 2026.
• U.S. system revenue grew by 25% to $23.4 million.
• U.S. handpiece and consumable revenue increased by 13% to $43.0 million.
• International revenue grew by 25% to $11.1 million.
• Gross margin improved to 65% in Q1 2026 from 64% in Q1 2025.
• The U.S. install base of Hydros systems increased by 40% year-over-year to 765 systems as of March 31, 2026.
• Received FDA clearance for its second-generation FirstAssist AI software.

Negatives

• Net loss increased to $31.6 million in Q1 2026 from $24.7 million in Q1 2025.
• Adjusted EBITDA loss widened to $18.1 million in Q1 2026 from $15.8 million in Q1 2025.
• Operating expenses increased by $15 million to $86.6 million, driven by investments.

Risks

• The company's forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from anticipated results.
• Risks and uncertainties are described more fully in the Company's filings with the SEC, including its annual report on Form 10-K and subsequent quarterly reports on Form 10-Q.

Future Outlook

The company reiterates its full-year 2026 guidance, expecting revenue between $390 million and $410 million (27%-33% growth), U.S. procedure growth of 39%-48%, gross margin of approximately 65%, and an Adjusted EBITDA loss between $30 million and $17 million.

Management Comments

• "Over the past six months, we have taken decisive actions to reset the organization by sharpening our focus on operational excellence, accountability, and commercial discipline, and our first quarter results reflect the early impact of that work."
• "We delivered $83.1 million in revenue, driven by strong U.S. system sales and improved pricing."
• "While our recent commercial realignment created some near-term disruption, the team is adapting quickly, and we expect the benefits to build through the year, driving sustained growth and improved profitability."

Industry Context

StockSavvy.ai notes that Procept Biorobotics' performance in Q1 2026, with a 20% revenue increase and 30% procedure growth, aligns with the broader trend of increasing adoption of robotic-assisted surgery in urology, driven by demand for minimally invasive and precise treatments for conditions like BPH.

Comparison to Industry Standards

• The company's revenue growth of 20% in Q1 2026 is strong compared to many medical device companies, especially those in specialized surgical fields.
• The 30% increase in U.S. procedures indicates significant market penetration and acceptance of Aquablation therapy, potentially outpacing the average growth rate for new surgical technologies.
• The gross margin of 65% is competitive within the medical device sector, particularly for companies with integrated hardware and consumable sales models.
• The net loss, while widening, is common for growth-stage medical technology companies investing heavily in R&D, commercial expansion, and clinical trials, a pattern seen across the industry.

Stakeholder Impact

• Shareholders: The report shows continued revenue growth and procedure volume increase, which are positive indicators for future value, but the widening net loss and Adjusted EBITDA loss may be a concern for profitability timelines.
• Employees: Increased operating expenses suggest continued investment in the workforce and commercial teams, potentially leading to expansion.
• Customers (Surgeons/Hospitals): The FDA clearance of the second-generation FirstAssist AI software enhances the HYDROS system, offering improved precision and planning for surgeons, potentially leading to better patient outcomes.
• Suppliers: Increased production to meet demand for systems and handpieces may lead to higher order volumes.

Next Steps

• Continue to drive sustained growth and improved profitability through the year.
• Build on the benefits of the recent commercial realignment.
• Continue investment in commercial expansion, innovation, and the WATER IV Prostate Cancer trial.
• Further advance the standard of care in urology through continued innovation.

Key Dates

Recommendation

The company demonstrates strong top-line growth and market penetration, with positive procedural volume increases and improved gross margins. However, the widening net loss and Adjusted EBITDA loss, despite reiterated guidance, suggest continued investment is impacting near-term profitability. The stock is likely to be valued on future growth potential, making it a hold for investors who believe in the long-term strategy but are cautious about the current profitability trajectory.

Keywords

Procept Biorobotics, Surgical Robotics, Urology, Aquablation Therapy, Hydros Robotic System, BPH, Q1 2026 Earnings, Financial Results